Down 3.2% today, more than its biotech peers' 1.4%; no story names it yet.
Down
Down 28% in 3 months while the S&P 500 fell 2%.
Follow RCKT's trial news. Pro members can get an alert when Rocket Pharmaceuticals files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Long-term trend | −3 |
| Latest filing | 8-K, Oct 6 |
TodayNo story names it yet.
Wed Nov 11: BioPharma Cell & Gene Therapy Nexus 2026Industry event · date confirmed.
After its last 4 reports it closed +0.9% on average, higher 1 of 4 times.
About 6 quarters
General Counsel Martin Wilson sold 53,389 shares on Nov 5. 22 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
RCKT is #202 of 281 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 202 |
Expected to report Thu Nov 12, after the close (in 2 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
The figures are not read from the release yet.
“The decrease of $13.2 million in R&D expenses was primarily driven by decreases in manufacturing and development and direct material costs of $7.5 million and stock-based and other compensation and benefit expenses of $3.6 million due to decreased R&D headcount, depreciation expenses of $1.0 million due to decreased asset base, and clinical trial expenses of $1.0 million.”
RCKT's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“The increase in other income was primarily driven by the sale of the Rare Pediatric Disease Priority Review Voucher for net $178.2 million.”
From its results filing (SEC filing · Aug 10)
Its share count grew 15% a year over 5 years.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Aug 10, 2026 | +0.6% | -3.9% | -6.6% |
| May 7, 2026 | +2.7% | -1.1% | -7.4% |
| Feb 26, 2026 | +1.3% | +10.6% | +2.4% |
Sales fell every year from 2018 to 2025, to $0. It lost money in each of the eight years.
RSI 46.8, MACD above signal, below both averages. Not scored.
5 insiders sold $743K across 12 filings in the last 6 months. No open-market buys on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: RCKT is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
“The biotechnology and pharmaceutical industries, including in the field of gene therapy, are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products and novel therapies.”
RCKT scores -4 today, which Breakaway calls Poor. It is #202 of 281 in Biotech by Quality Score, with 3 of 14 chart checks firing. Down 28% in 3 months while the S&P 500 fell 2%. Cash lasts about 6 quarters at its spending (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
RCKT scores -4 today, which Breakaway calls Poor (below zero). That is #202 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind RCKT's -4.
5 insiders sold $743K across 12 filings in the last 6 months. No open-market buys on record. The newest is Martin Wilson, General Counsel, who sold $128K on Nov 5. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Thursday morning. No account. No card. Then keep going with a free account.